Phenibut complete reference · Evidence first
Phenibut, mapped from chemical identity to current public-health evidence
In practice, this Phenibut complete reference organizes the most useful verifiable material into one research pathway: identity, nomenclature, stereochemistry, experimental pharmacology, human-evidence limitations, toxicology surveillance, analytical detection, product-quality studies, history, regulation, and unresolved questions.
The Phenibut complete reference separates statements by evidence type. For example, findings from receptor assays or animal models are not presented as proof of human benefit. In contrast, poison-center reports describe reported exposures rather than population incidence. In addition, case reports can identify hazards but cannot establish a universal dose-response relationship. Therefore, where a claim cannot be traced confidently, it is labeled unresolved.
Chemical identity in the Phenibut complete reference
Specifically, Phenibut is commonly used as the English name for 4-amino-3-phenylbutanoic acid, also described as β-phenyl-γ-aminobutyric acid or beta-phenyl-GABA. However, the free base and hydrochloride salt are related but distinct chemical records and should not be assigned the same CAS number.
Phenibut
- CAS
- 1078-21-3
- Formula
- C10H13NO2
- Molar mass
- 179.22 g/mol
Phenibut HCl
- CAS
- 3060-41-1
- Formula
- C10H14ClNO2
- Molar mass
- 215.68 g/mol
In addition, frequently encountered names include Phenibut, Fenibut, PhGABA, phenyl-GABA, and several historical or regional names. In practice, a name alone is not sufficient identification: the form, stereochemical context, analytical result, lot, and source record all matter. Therefore, see the nomenclature guide, identifier guide, and free-base versus hydrochloride comparison.
Evidence map for the Phenibut complete reference
Chemistry
For example, this domain covers identity, salt form, molecular structure, stereochemistry, synonyms, and structure-derived records.
Experimental pharmacology
Specifically, this domain covers receptor binding, optical-isomer comparisons, calcium-channel-subunit findings, and animal models.
Human literature
Meanwhile, this domain covers older clinical reports, modern systematic reviews, case reports, and major limitations in study design.
Toxicology
In addition, this domain covers national poison-center surveillance, regional series, clinical case literature, and fatality reports.
Analytical science
For instance, this domain covers HPLC, LC–MS/MS, GC–MS limitations, forensic detection, and product-composition studies.
History
By contrast, this domain separates Soviet research provenance and later English-language reviews from repeated lore.
Regulation
Similarly, this domain connects FDA records, WHO review and surveillance, enforcement documents, and jurisdiction-specific controls.
Evidence quality
Finally, this domain explains how to evaluate reviews, case reports, animal work, surveillance, inaccessible sources, and online reports.
Experimental pharmacology in the Phenibut complete reference
Importantly, Phenibut is a structural analogue of GABA, but structural similarity is not itself proof of a particular effect. Therefore, the clearest modern experimental work separates the two optical isomers and distinguishes receptor systems.
GABAB findings
For example, a 2008 study compared racemic Phenibut with its optical isomers in receptor-binding and animal experiments. The results attributed much of the measured GABAB-related activity to the R-isomer. However, this is preclinical evidence, not a human efficacy trial.
α2δ findings
In addition, a 2015 study reported binding of Phenibut isomers at the α2δ subunit of voltage-dependent calcium channels and evaluated antinociceptive effects in animal models. Nevertheless, it does not establish a clinical indication.
Gabapentin-site assay
By comparison, a separate 2016 study reported binding at the gabapentin site and activity in rat pain models, with stronger results for the R-isomer. Moreover, industry affiliations disclosed on the PubMed record are relevant context when weighing the evidence.
Translation remains unresolved
However, binding affinity, animal behavior, and disease-model results do not establish human safety, effectiveness, dosing, or suitability. Instead, those questions require appropriately designed human research.
Human evidence limits in the Phenibut complete reference
Within this Phenibut complete reference, publication volume is not confused with a large body of modern controlled human trials. Much of the clinical narrative traces through older Russian-language sources, later reviews, case reports, and poison-center data. Moreover, access limitations and citation-chain problems can make independent verification difficult.
| Evidence source | What it contributes | What it cannot establish alone |
|---|---|---|
| Older clinical literature | Historical observations and reported clinical use in certain countries | Modern standards of efficacy, bias control, generalizability, or U.S. approval |
| Systematic reviews | Organized maps of available trials, intoxication reports, and withdrawal cases | Certainty greater than the underlying studies or complete access to unavailable papers |
| Case reports and series | Detailed descriptions of unusual, severe, or clinically important presentations | Incidence, prevalence, comparative risk, or a universal threshold |
| Poison-center surveillance | Reported exposure patterns, outcomes, and public-health signals | Population incidence or laboratory confirmation in every report |
| Online-report research | Qualitative information about self-reported motivations and experiences | Verified identity, controlled exposure, causality, or representative prevalence |
For example, three recent systematic reviews are useful entry points: the 2023 review of toxicity and withdrawal presentations, a 2023 withdrawal-focused review, and a 2024 systematic review of published withdrawal cases. However, they organize clinical reports without creating a validated treatment protocol or a safe-use standard. Therefore, read the original records: Weleff et al., Feldman et al., and Stewart et al..
Toxicology and surveillance in the Phenibut complete reference
However, the CDC analysis includes both single- and multiple-substance reports and explains important limitations: exposures were reported rather than necessarily analytically confirmed; not every exposure is reported to a poison center; and the database terminology changed during the study period. Therefore, the data are a safety signal, not a denominator-based incidence estimate and not a basis for calculating a lethal amount.
Read the complete CDC report
Specifically, methods, demographics, reported effects, outcome categories, and the authors’ limitations are available in the original MMWR record.
Similarly, clinical reviews describe both intoxication and withdrawal presentations, but the site does not reproduce individual consumption amounts, medication substitutions, taper arithmetic, or treatment protocols. Consequently, suspected exposure requires individualized advice from Poison Control or emergency professionals.
Analytical detection in the Phenibut complete reference
Absence from a routine screen is not proof of absence
In practice, Phenibut is not normally identified by standard urine immunoassay panels. However, targeted chromatographic and mass-spectrometric methods have been described in forensic literature.
Targeted screening and quantification
For example, a 2024 forensic study developed LC–MS/MS screening and quantification methods and applied them to driving-under-the-influence casework. Nevertheless, interpretation remains limited by sparse concentration data.
Thermal-analysis complication
In particular, published work documents analytical challenges caused by thermal cyclization under conventional GC–MS conditions and describes modified approaches. Therefore, method choice and standards matter.
Labels cannot substitute for testing
Similarly, small product-analysis studies found discrepancies between labeling and measured composition. Although their sample sizes do not justify claims about every supplier, they demonstrate why identity and lot-level analysis matter.
In addition, a 2022 four-brand study found that measured Phenibut quantities varied across products and time points after FDA warnings. However, it evaluated products marketed as dietary supplements and should not be generalized beyond the samples tested. Read Cohen et al. on PubMed.
History and source provenance in the Phenibut complete reference
Historically, the English-language literature places Phenibut’s development in the Soviet Union during the twentieth century. However, common retellings often compress early synthesis, pharmacological development, registration, and later space-program anecdotes into a single story. Therefore, this Phenibut complete reference points to the Primary Documents Archive, which separates accessible records from secondary citation chains and labels claims whose primary documentation remains unavailable.
For example, this category includes published chemistry and pharmacology records, named researchers, later reviews, and identifiable regulatory documents.
By contrast, this category includes historical therapeutic use and product registration in specific countries and periods.
Finally, this category includes repeated anecdotes for which accessible primary documentation has not been located.
Regulatory orientation in the Phenibut complete reference
Importantly, regulatory questions are product-, claim-, jurisdiction-, customer-, and date-specific. In the United States, FDA states that Phenibut does not meet the statutory definition of a dietary ingredient. Moreover, an April 2026 FDA public-health alert again described Phenibut as unlawful in dietary supplements. In addition, FDA warning letters demonstrate that website copy and label claims can be evidence of intended drug use.
FDA April 2026 alertRecent public-health and product action
WHO pre-reviewExpert Committee review materials
WHO surveillance updatePhenibut remains under surveillance
Therefore, for dated jurisdictional context and source links, use the legal-status reference and regulatory dossier. Nevertheless, neither page substitutes for advice from qualified counsel about a specific transaction or business model.
Community-report evidence in the Phenibut complete reference
Meanwhile, online reports can reveal vocabulary, motivations, recurring concerns, and questions that deserve formal study. However, they cannot verify chemical identity, amount, co-exposures, medical history, or causality. For example, a 2023 mixed-methods study analyzed 229 online reports involving Phenibut and related substances; its findings describe the submitted corpus, not all users. Therefore, read the study or visit the site’s community-evidence analysis.
Unknowns identified by the Phenibut complete reference
Modern controlled human evidence
At present, the accessible evidence does not provide a robust set of independently replicated, well-controlled human trials meeting modern standards.
Human pharmacokinetics
Similarly, frequently repeated parameters often trace to limited or difficult-to-verify sources. In addition, product form and study conditions are not always clear.
Standardized toxicology confirmation
Meanwhile, routine clinical screening generally does not identify Phenibut, complicating surveillance and case attribution.
Comparative clinical management
Likewise, recent reviews emphasize case-based management literature and the absence of comparative treatment trials.
International and historical access
Furthermore, older Russian-language papers, theses, and institutional records remain incompletely digitized, translated, or independently appraised.
Representative prevalence
Finally, poison-center calls, case reports, and online narratives do not provide a representative estimate of use or harm in the general population.
Key sources for the Phenibut complete reference
The Phenibut complete reference connects to the full 148-record research library, searchable by title, author, journal, year, PMID, decade, and subject. In addition, these selected records are useful starting points:
Safety synthesis · 2020Kupats et al.: safety and tolerability literatureMaps older trials and case reports while exposing limitations in the evidence base.
Toxicology synthesis · 2023Weleff et al.: toxicity and withdrawal presentationsClinical literature map; not a validated self-treatment protocol.
Withdrawal synthesis · 2023Feldman et al.: withdrawal complicationsWithdrawal-focused case synthesis with single- versus polysubstance context.
Clinical review · 2024Penzak and Bulloch: pharmacology and clinical literatureNotes the lack of comparative withdrawal-treatment studies.
Research-needs review · 2024Gurley and Koturbash: toxicology and research needsReviews pharmacology, adverse effects, screening gaps, and associated toxicities.
German context · 2024Bonnet et al.: German clinical and regulatory perspectiveIncludes regional poison-center observations and jurisdiction-specific context.
National surveillance · 2020CDC: U.S. poison-center exposures, 2009–2019Original methods, outcomes, and reporting limitations.
Frequently asked questions about the Phenibut complete reference
Is Phenibut the same chemical record as Phenibut HCl?
They are not the same record: the free base and hydrochloride salt have different formulas, molar masses, and CAS records. Therefore, a technical document should identify the exact form.
Does a large publication count prove effectiveness?
In practice, publication count does not measure study quality. Instead, reviews, case reports, animal studies, analytical papers, and surveillance reports answer different questions.
Is Phenibut approved by FDA?
In the United States, FDA has not approved Phenibut as a drug and states that it does not meet the statutory definition of a dietary ingredient.
Has a reliable human lethal dose been established?
A reliable universal lethal amount has not been established. Consequently, individual reports and animal LD50 data should not be converted into a predicted human threshold.
Does this page contain dosing or withdrawal instructions?
This reference intentionally excludes consumption guidance, taper schedules, medication substitutions, route advice, and combination instructions.
How can researchers find every indexed study?
First, use the searchable research library, its disclosed PubMed query, DOI links, and the broader discovery links to PubMed and Crossref. However, no single database captures every thesis, patent, conference item, or foreign-language record.
In the United States, contact Poison Control at 1-800-222-1222. Call 911 if a person has collapsed, is having a seizure, has trouble breathing, or cannot be awakened.
Scope, independence, and research-use boundary
This page is an educational index and evidence synthesis, not medical or legal advice. It is not a recommendation for consumption and intentionally excludes human-use dosing, cycling, tapering, route, combination, and self-treatment instructions. Citations describe external publications and do not imply endorsement, verification of every conclusion, or equivalence between a studied material and any material offered by Northeast Research Supply. Materials offered by Northeast Research Supply are for legitimate laboratory, analytical, scientific, and educational research only and are not for human or animal consumption.